1. Clinical & Scientific Overview
Donepezil Hydrochloride (TIP-MED-000215, Reference Code [11.11]) is classified under
Neurology & Antiepileptic Medicines (Ch 11) as a Centrally Acting Reversible Acetylcholinesterase Inhibitor (AChEI; Enhances Cholinergic Synaptic Transmission in Cerebral Cortex & Hippocampus).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 11 [11.11], p. 145): Aricep (Eisai/Sun Pharma), Donep (Alkem), Alzil (Intas), Dopezil, Cogniza; In FDC with Memantine: Aricep-M, Donep-M, Alzil-M — Strengths & Dosage Forms: Oral Film-Coated & Orally Disintegrating (ODT) Tablets: 5 mg, 10 mg (also 23 mg SR in severe AD); Common FDCs: Donepezil 5 mg + Memantine 5 mg OR Donepezil 5 mg + Memantine 10 mg
Oral Film-Coated & Orally Disintegrating (ODT) Tablets: 5 mg, 10 mg (also 23 mg SR in severe AD); Common FDCs: Donepezil 5 mg + Memantine 5 mg OR Donepezil 5 mg + Memantine 10 mg
3. Mechanism of Action & Pharmacodynamics
Centrally Acting Reversible Acetylcholinesterase Inhibitor (AChEI; Enhances Cholinergic Synaptic Transmission in Cerebral Cortex & Hippocampus) acting on target receptor/enzyme pathways in Neurology & Antiepileptic Medicines (Ch 11): clinical efficacy is mediated via Centrally Acting Reversible Acetylcholinesterase Inhibitor (AChEI; Enhances Cholinergic Synaptic Transmission in Cerebral Cortex & Hippocampus) for Symptomatic cognitive and functional stabilization in mild, moderate, and severe Alzheimer's Disease, mixed Alzheimer's-vascular dementia, and Lewy body / Parkinson's disease dementia..
4. Therapeutic Indications & Evidence-Supported Uses
- Symptomatic cognitive and functional stabilization in mild, moderate, and severe Alzheimer's Disease, mixed Alzheimer's-vascular dementia, and Lewy body / Parkinson's disease dementia
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: Initiate at 5 mg once daily for at least 4 to 6 weeks! (Wait a full 4–6 weeks for steady state [t1/2 ~70 hours] and cholinergic GI adaptation before increasing to 10 mg once daily; escalating earlier than 4 weeks causes severe vomiting and bradycardia!). Follow neurologist/psychiatrist prescription.
Administration & Meal Timing: With or without food (taking after dinner reduces cholinergic nausea). | Usually taken at BEDTIME (so peak plasma cholinergic activity occurs during sleep, minimising nausea and dizziness—HOWEVER, if the patient develops vivid cholinergic nightmares or insomnia, switch administration to the MORNING after breakfast!).
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Renal clearance of unchanged donepezil does not vary significantly with CrCl; no dose adjustment needed in mild-to-severe CKD. Hepatic: Clearance reduced by ~20% in mild-to-moderate alcoholic cirrhosis; titrate cautiously.
Renal: Renal clearance of unchanged donepezil does not vary significantly with CrCl; no dose adjustment needed in mild-to-severe CKD. Hepatic: Clearance reduced by ~20% in mild-to-moderate alcoholic cirrhosis; titrate cautiously.
Renal: Renal clearance of unchanged donepezil does not vary significantly with CrCl; no dose adjustment needed in mild-to-severe CKD. Hepatic: Clearance reduced by ~20% in mild-to-moderate alcoholic cirrhosis; titrate cautiously.
7. Contraindications, Precautions & High-Risk Warnings
- 1. Cardiac Vagal Conduction Precaution: Donepezil increases vagal cholinergic tone on the sinoatrial and atrioventricular nodes—use with extreme caution in Sick Sinus Syndrome, Sinus Bradycardia (<50–55 bpm), Sinoatrial or AV Nodal Block, or unexplained syncope! 2. Gastrointestinal & Respiratory Precaution: Cholinergic stimulation increases gastric acid secretion (caution in active peptic ulcer or NSAID users) and bronchial smooth muscle tone (caution in severe asthma/COPD); can worsen bladder outflow obstruction.
Key Clinical Precautions: Renal: Renal clearance of unchanged donepezil does not vary significantly with CrCl; no dose adjustment needed in mild-to-severe CKD. Hepatic: Clearance reduced by ~20% in mild-to-moderate alcoholic cirrhosis; titrate cautiously.
8. Adverse Effects Profile
- Cholinergic GI Effects (10–20%, especially during initiation or escalation to 10 mg): Nausea, vomiting, loose stools/diarrhoea, anorexia/weight loss, muscle cramps, fatigue, vivid dreams/nightmares and insomnia, urinary frequency/urge incontinence.
- Severe Symptomatic Sinus Bradycardia, Complete AV Heart Block, and Syncope (leading to falls and hip fractures!), gastrointestinal ulceration and bleeding, seizures, extrapyramidal symptoms, rhabdomyolysis/neuroleptic malignant-like syndrome (rare).
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- PHARMACODYNAMIC ANTAGONISM ('The Dementia-Bladder Prescribing Cascade'): NEVER combine Donepezil with Central/Systemic Anticholinergic Drugs (Oxybutynin, Tolterodine, Solifenacin, Trihexyphenidyl [Pacitane], Amitriptyline, Hydroxyzine [Atarax], Chlorpheniramine, Promethazine)! Donepezil works by boosting acetylcholine in the brain, while anticholinergics directly block acetylcholine receptors—cancelling out Donepezil and plunging the dementia patient into acute delirium! 2
- Synergistic Bradycardia & Syncope: Combining Donepezil with Beta-Blockers (Metoprolol, Atenolol, Bisoprolol, Carvedilol), Non-DHP CCBs (Diltiazem, Verapamil), Digoxin, or Amiodarone causes severe additive bradycardia and heart block! 3
- CYP2D6 & CYP3A4 Inhibitors (ketoconazole, paroxetine, fluoxetine) increase donepezil levels
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: 1. Counsel the family caregiver on realistic expectations: 'Aricep/Donep helps keep memory, daily recognition, and conversation steadier for longer—even if memory does not dramatically improve back to 10 years ago, staying stable means the medicine is working!' 2. If taking it at bedtime causes vivid disturbing dreams, shift the tablet to morning after breakfast. 3. Warn Against the Bladder Cascade: Donepezil often causes mild urinary urgency; warn caregivers never to let another clinic start an anticholinergic bladder tablet (like Oxybutynin or Tolterodine) for this urgency, as bladder anticholinergics wipe out Donepezil's brain benefit (Mirabegron is used instead if needed!).
- Meal & Clock Timing Instruction: With or without food (taking after dinner reduces cholinergic nausea). (Usually taken at BEDTIME (so peak plasma cholinergic activity occurs during sleep, minimising nausea and dizziness—HOWEVER, if the patient develops vivid cholinergic nightmares or insomnia, switch administration to the MORNING after breakfast!).)
- Missed Dose Protocol: Take the next day at the scheduled time (because elimination half-life is 70 hours, missing 1 single tablet is benign; however, if Donepezil is interrupted for >7–14 days while on the 10 mg dose, re-initiate at 5 mg OD for 4 weeks to prevent violent cholinergic vomiting!).
- Geriatric Dispensing Pearl: Check the radial pulse of every elderly CGHS dementia patient on Donepezil (especially if they also take Metoprolol, Bisoprolol, or Digoxin for heart disease)—unrecognised cholinergic bradycardia (<48 bpm) is a major cause of unexplained syncope and hip fractures in dementia patients!
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Film-Coated & Orally Disintegrating (ODT) Tablets: 5 mg, 10 mg (also 23 mg SR in severe AD); Common FDCs: Donepezil 5 mg + Memantine 5 mg OR Donepezil 5 mg + Memantine 10 mg
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 11 [11.11] (p. 145)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [11.14] Phenobarbitone (Phenobarbital) & Clobazam — Barbiturate & 1,5-Benzodiazepine Antiepileptics (GABA-A Allosteri
- [11.15] Diazepam (Oral, IV & Paediatric Rectal Protocol) — Long-Acting Lipophilic Benzodiazepine (Anticonvulsant, Anxiolytic
- [11.16] Midazolam (Parenteral & Intranasal Rescue Protocol) — Short-Acting Water-Soluble Imidazobenzodiazepine (Intranasal / Bu
- [11.27] Levodopa + Carbidopa (Co-Careldopa) & Pramipexole — Dopamine Precursor + Peripheral DOPA Decarboxylase Inhibitor & No
